Determination of the levels of brain natriuretic peptide and its N-terminal fragment for the evaluation of the efficiency of renal replacement therapy modalities in patients with decompensated chronic heart failure
- Authors: Tabakyan EA1, Zaruba AY.1, Rogoza AN1, Ataullakhanova DM1, Kukharchuk VV1
-
Affiliations:
- A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
- Issue: Vol 82, No 8 (2010)
- Pages: 24-29
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30620
- ID: 30620
Cite item
Full Text
Abstract
Subjects and methods. Patients (31 men and 9 women) aged 30 to 82 years with functional class II-IV CHF in its decompensation phase were examined. The patients were divided into 2 groups. A study group received medical therapy for CHF, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, verospirone, β-adrenoblockers, digoxin, loop diuretics (furosemide, diuver, in the doses not exceeding those taken before admission) in combination with renal replacement therapy: slow continuous ultrafiltration (SCUF) or continuous venovenous hemofiltration (CVVHF). A control group had only medical therapy for CHF (intravenous furosemide in the doses doubling those used before admission, i.e. l 80 mg/day required for an adequate response to the drug - daily urine volume > 1 liter). The patients from the study and control groups received furosemide m 40 mg/day or torsemide m 20 mg/day after a course of SCUF or CVVHF sessions or intravenous furosemide. There were 4 examination stages [control study points (CSP)]: 1) before study; 2) after CHF compensation achievement (a day before hospital discharge); 3) following 90 days; 4) following 180 days. The plasma concentration of active BNP was measured by enzyme immunoassay; that of the N-terminal fragment of BNP (NT-proBNP) was estimated on an analyzer.
Results. There were direct correlations between the content of BNP and that of NT-proBNP) in all CSPs in the patients from both groups. The study group showed a significantly greater weight loss, which was accompanied by a more pronounced reduction in systolic pulmonary artery pressure, pulmonary venous hypertension, hydrothorax elimination, decreased liver size, lower plasma aldosterone concentration, decreased heart size, and higher left ventricular ejection fraction (LVEF). The study group displayed a steady-state reduction in the plasma concentrations of both BNP and NT-proBNP, significant inverse correlations between the lower BNP level and the higher LVEF throughout the follow-up.
Conclusion. Extracorporeal dehydration techniques are more effective that intravenous diuretics. The direct correlations between the content of BNP and that of NT-proBNP and between the change in their concentrations during treatment assume the capacity and objectification of diagnosing CHF and its degree, by determining only one of the types of BNP.
About the authors
E A Tabakyan
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
Email: tabakyan@mail.ru
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
A Yu Zaruba
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
Email: zaruba_a@rambler.ru
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
A N Rogoza
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, MoscowA. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
D M Ataullakhanova
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, MoscowA. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
V V Kukharchuk
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
Email: v_kukharch@mail.ru
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
References
- Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Сердеч. недостат. 2005; 7: 52-78.
- Маршалл В. Дж. Клиническая биохимия. М.: БИНОМ; СПб.: 2000. 69-78.
- Adams K. F., Fonarow G. C., Emerman C. L. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 2005; 149: 209-216.
- Mehrotra R., Khanna R. Peritoneal ultrafiltration for chronic congestive heart failure: rationale, evidence and future. Cardiology 2001; 96: 177-182.
- Agostoni P. G., Marenzi G. C. Sustained benefit from ultrafiltration in moderate congestive heart failure. Cardiology 2001; 96: 183-189.
- Costanso M. R., Guglin M. E., Saltsberg M. T. et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 2007; 49: 675-683.
- Dao Q., Krishnaswamy P., Kazanegra R. et al. Utility of B-natriuretic peptide in the diagnosis of congestive heart failure in an type urgent-care setting. J. Am. Coll. Cardiol. 2001; 37: 379-385.
- Maisel A. S., Krishnaswamy P., Nowak R. M. et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 2002; 347: 161- 167.
- Hunt P. J., Yandle T. G., Nicholls M. G. et al. The amino-terminal portion of pro-brain natriuretic peptide (pro-BNP) circulates in human plasma. Biochem. Biophys. Res. Commun. 1995; 214: 1175-1183.
- Hunt P. J., Richards A. M., Nicholls M. G. et al. Immunoreactive amino- terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin. Endocrinol. 1997; 47: 287-296.
- Januzzi J. L. Jr., Camargo C. A., Anwaruddin S. et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 2005; 95: 948- 954.
- Felker G. M., Petersen J. W., Mark D. B. Natriuretic peptides in the diagnosis and management of heart failure. Can. Med. Assoc. J. 2006; 175 (6): 611-617.
- Hunt S. A., Abraham W. T., Chin M. H. et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005; 112: е187-e189.
- Levey A. S., Coresh J., Balk E. et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 2003, 139: 137-147.
- Bart B. A., Boyle A., Bank A. J. et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J. Am. Coll. Cardiol. 2005; 46: 2043-2046.
- Lainchbury J. G., Campbell E., Frampton C. M. et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J. Am. Coll. Cardiol. 2003; 42: 728-735.
![](/img/style/loading.gif)